title: Evaluation of short-chain polypeptides as an osmotic agent in continuous ambulatory peritoneal dialysis patients.
abstract: OBJECTIVE
  To assess whether dialysate containing short-chain polypeptides is well tolerated in continuous ambulatory peritoneal dialysis (CAPD) patients and to determine its effect on fluid and solute transport, plasma amino acid levels, and biochemical parameters.
  
  
  METHODS
  Two-treatment, two-period cross-over design.
  
  
  METHODS
  Renal Unit, Academic Medical Center, Amsterdam and Renal Unit, University Hospital, Gent.
  
  
  METHODS
  Two groups of 10 stable CAPD patients.
  
  
  METHODS
  All patients received a trial solution (1.36% glucose and 1% peptides, 381 mOsm/kg) and a control solution (2.27% glucose, 404 mOsm/kg) in randomized order. The patients were examined on four consecutive days in which two dwell periods on days 1 and 3 of either 4 (Group I) or 8 hours (Group II) were performed.
  
  
  RESULTS
  The peptide solution was well tolerated in all patients. In addition, no differences were found in the parameters for the effective peritoneal surface area and the intrinsic permeability, implying that no irritating effect of the peptide solution was present. Net ultrafiltration was not different in Group I: -43 +/- 125 versus 86 +/- 125 mL (mean +/- SEM) and marginally lower in Group II: -94 +/- 64 versus 51 +/- 64 mL, despite the lower osmolality of the trial solution compared to the control solution. Glucose absorption was higher than the peptide absorption in all patients: Group I: 66 +/- 10% versus 57 +/- 13% (p = 0.0003); Group II: 80 +/- 5% versus 72 +/- 11% (p = 0.006). No differences in plasma amino acid profiles could be detected.
  
  
  CONCLUSIONS
  Short-chain polypeptides are absorbed less than glucose and can be used as an osmotic agent in CAPD patients. However, longer-term studies are needed to evaluate possible additional effects of peptides on the nutritional status of CAPD patients.
authors.affiliation: Department of Medicine, University of Amsterdam, The Netherlands.
authors.forename: A L
authors.initials: AL
authors.lastname: Imholz
authors.forename: N
authors.initials: N
authors.lastname: Lameire
authors.forename: D
authors.initials: D
authors.lastname: Faict
authors.forename: G C
authors.initials: GC
authors.lastname: Koomen
authors.forename: R T
authors.initials: RT
authors.lastname: Krediet
authors.forename: L
authors.initials: L
authors.lastname: Martis
mesh_terms: D000328:Adult; D000368:Aged; D000596:Amino Acids / Q000097:blood; D018592:Cross-Over Studies; D015314:Dialysis Solutions / Q000009:adverse effects; D005260:Female; D005947:Glucose / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D010455:Peptides / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010531:Peritoneal Dialysis, Continuous Ambulatory
chemical_list: D000596:Amino Acids; D015314:Dialysis Solutions; D010455:Peptides; D005947:Glucose